BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Paragon Therapeutics Inc.

Headquarters: Boston, MA, United States
Year Founded: 2021
Status: Private

BioCentury | Nov 26, 2024
Management Tracks

Susanna High named CEO of Paragon

Plus: Lee Patterson becomes CEO of Metrion, and updates from Rondo, AffyImmune and Aspargo
BioCentury | Nov 14, 2024
Deals

More BD in Akeso’s wake: Merck buys into LaNova’s bispecific for $588M up front

Marketer of Keytruda takes rights to bifunctional molecule in class that could compete directly with its top seller
BioCentury | Nov 14, 2024
Deals

Already partners on bispecific, BioNTech buys Biotheus for $800M

Along with potential Keytruda competitor, German biotech gains pipeline, bispecific platform, and China sites via acquisition
BioCentury | Nov 1, 2024
Finance

How Fairmount’s Paragon incubator steered two more companies to NASDAQ

In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
BioCentury | Aug 9, 2024
Finance

Venture Report: Pair of crossover rounds for precision oncology, peptide biotechs

Plus: Financings for newcos Nilo, Jade, Red Queen
BioCentury | Apr 6, 2024
Finance

Public equity report: Contineum’s NASDAQ listing, Oruka’s financing-merger combo

Plus: Surrozen and Sutro raise cash, and Redx proposes to delist from London’s AIM
BioCentury | Jul 15, 2023
Finance

Upsized deals by Sagimet, Apogee latest sign of thawing IPO market

Apogee’s $300M raise NASDAQ’s second largest IPO of the year, first significant preclinical debut on exchange since last fall
BioCentury | Jul 14, 2023
Finance

July 13 Quick Takes: Apogee prices $300M IPO

Plus: New funds for BGV, Modi; Arix reviewing alternatives; and updates from Bicycle, Roche, Causaly, Neuren-Acadia  
BioCentury | Jun 23, 2023
Finance

How Apogee will test the IPO market’s appetite for preclinical risk

Backed by Fairmount Funds and Venrock and spun out of Paragon, the young start-up has an experienced CFO and is aiming for familiar targets
BioCentury | Jun 23, 2023
Deals

June 22 Quick Takes: Spyre launches onto NASDAQ via Aeglea merger

Plus: Tourmaline reverse-merging with Talaris, CAR T shows early efficacy in myasthenia gravis, and updates from AltPep, Solve and Intercept
Items per page:
1 - 10 of 12